Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 9/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | PKM | P14618 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 6/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337924 | 0.90 | S1PR3 (0.62) | S1PR3MAPTPKMGAAALDH1A1 | |
| SCHEMBL337867 | 0.89 | S1PR3 (0.61) | S1PR3MAPTPKMGAAALDH1A1 | |
| SCHEMBL291421 | 0.88 | S1PR3 (0.65) | S1PR3MAPTPKMGAAALDH1A1 | |
| SCHEMBL337715 | 0.88 | S1PR3 (0.60) | S1PR3MAPTPKMGAAALDH1A1 | |
| SCHEMBL336878 | 0.87 | S1PR3 (0.64) | S1PR3MAPTPKMGAAALDH1A1 | |
| SCHEMBL337035 | 0.86 | S1PR3 (0.63) | S1PR3MAPTPKMGAAALDH1A1 | |
| SCHEMBL336671 | 0.85 | MAPT (0.73) | S1PR3MAPTPKMGAAALDH1A1 | |
| SCHEMBL337897 | 0.82 | MAPT (0.76) | S1PR3MAPTPKMGAAALDH1A1 | |
| SCHEMBL2003321 | 0.82 | S1PR3 (0.60) | S1PR3MAPTPKMGAAALDH1A1 | |
| SCHEMBL2004606 | 0.81 | S1PR3 (0.57) | S1PR3MAPTPKMGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097644-B2 | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2012-01-17 | — | — | US | claimed |
| EP-2262497-A2 | S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION | Allergan, Inc. (US) | 2010-12-22 | — | — | EP | claimed |
| WO-2009117335-A2 | S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION | ALLERGAN, INC. (US) | 2009-09-24 | — | — | WO | claimed |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2007-10-04 | — | — | US | claimed |
| WO-2007112322-A2 | INDOLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2007-10-04 | — | — | WO | claimed |
| US-20140011771-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011771-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011771-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8563594-B2 | S1P3 receptor inhibitors for treating pain | ALLERGAN, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563594-B2 | S1P3 receptor inhibitors for treating pain | ALLERGAN, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563594-B2 | S1P3 receptor inhibitors for treating pain | ALLERGAN, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120071448-A1 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye | ALLERGAN, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2009117335-A2 | S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION | ALLERGAN, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008141013-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141013-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| WO-2007112322-A2 | INDOLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007112322-A2 | INDOLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011771-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | S1PR3, LPAR3, S1PR2 | S1PR3 1/4885MAPT 3312/4885PKM 2472/4885 |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | S1PR1, S1PR2, S1PR3 | S1PR3 3/4885MAPT 4413/4885PKM 3273/4885 |
| US-20120071448-A1 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye | S1PR3, S1PR1, S1PR2 | S1PR3 1/4885MAPT 3541/4885PKM 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.